Doximity's SWOT analysis: digital health leader faces growth challenges

Doximity (DOCS), a digital platform for medical professionals, reported strong Q4 2025 results with revenue of $138.3 million, a 17% year-over-year increase, and adjusted EBITDA of $69.7 million, up 24%. While Doximity's fiscal year 2026 revenue guidance of $619-$631 million indicates a potential growth slowdown to approximately 10%, below consensus estimates, the company is focusing on AI integration and strategic acquisitions to drive long-term growth; however, macroeconomic uncertainties and a premium valuation (P/E of 45.72) pose potential headwinds.

Analysis

Doximity, Inc. (DOCS) reported robust fiscal fourth-quarter 2025 results, with revenue climbing 17% year-over-year to $138.3 million, surpassing market expectations, and adjusted EBITDA reaching $69.7 million, a 24% increase, yielding an impressive 50.4% EBITDA margin. The company's financial health is rated as "GREAT" (3.39 out of 5 by InvestingPro), supported by exceptional gross profit margins of 90.2% and a 19.98% revenue growth over the last twelve months. However, Doximity's guidance for fiscal year 2026 projects revenue between $619 million and $631 million, indicating a decelerated year-over-year growth of approximately 10%, slightly below the consensus estimate of $634.6 million. This cautious outlook reflects potential macroeconomic uncertainties, including drug pricing reforms and tariffs, which could impact pharmaceutical spending—a key revenue driver. Despite this, Doximity maintains a strong market position with its network of over 2 million medical professionals and is actively investing in AI to enhance prescriber engagement and expanding its offerings through strategic acquisitions like Curative Talent and AMiON. The company trades at a premium valuation, with a P/E ratio of 45.72 and an estimated FY2026 enterprise value to EBITDA ratio of approximately 29x, significantly above the industry average of 17x, which InvestingPro’s Fair Value analysis suggests may be slightly overvalued.

Key Decisions for Investors

• Investors should acknowledge Doximity's strong current profitability and market leadership but exercise caution due to the projected slowdown in revenue growth for FY2026 and its premium valuation.
• Monitor the impact of AI investments on user engagement and revenue, alongside pharmaceutical industry spending trends, as these will be critical drivers for sustaining growth.
• Consider the balance between Doximity's long-term growth potential, driven by the healthcare industry's digital shift and AI integration, against near-term macroeconomic headwinds and the current high valuation multiples before adjusting positions.